Feature | August 19, 2013

Medtronic Submits Drug-Eluting Balloon for FDA Review

Vendor hopes for pre-market approval for novel peripheral angioplasty device in second half of 2015

August 19, 2013 — Medtronic Inc. announced the submission of its first pre-market approval (PMA) module to the U.S. Food and Drug Administration (FDA) for the IN.PACT Admiral drug-eluting balloon. Designed to treat atherosclerotic lesions in the superficial femoral artery (SFA), the novel angioplasty device remains investigational in the United States.

“Pending FDA approval, we remain on track to launch the IN.PACT Admiral drug-eluting balloon in the United States during the second half of calendar year 2015,” said Tony Semedo, president of Medtronic’s Endovascular Therapies business. “In the meantime, we will continue working with leading healthcare providers and researchers around the world to amass clinical and economic evidence to support the global adoption of this innovative medical technology as an important addition to the treatment options for peripheral artery disease in the lower extremities.”

The ongoing global clinical program of IN.PACT drug-eluting balloons for the treatment of peripheral artery disease (PAD) in the lower extremities includes 24 studies involving more than 4,200 patients at approximately 230 sites worldwide. A combination of physician-initiated and company-sponsored studies, the program will fully characterize the safety and efficacy of these combination devices in a variety of peripheral vascular beds, including below-the-knee arteries.

Medtronic’s PMA application for the IN.PACT Admiral drug-eluting balloon will include clinical data from the IN.PACT SFA I and SFA II pivotal studies, the IN.PACT SFA II pharmacokinetics (PK) study, and the IN.PACT Global study, which have enrolled a total of more than 1,000 patients to date.

IN.PACT drug-eluting balloons feature a proprietary coating called FreePac that is a formulation of the antiproliferative drug paclitaxel and the biocompatible excipient urea, which facilitates rapid absorption of the drug into the vessel wall.

Several IN.PACT drug-eluting balloons received CE mark in 2008 and 2009 and are available in many countries around the world. In the United States, the IN.PACT Admiral drug-eluting balloon is limited to investigational use, and, like all drug-eluting balloons, is not yet commercially available.

The treatment of PAD varies by stage of progression and other factors, with lifestyle modifications aimed at risk factor reduction recommended for all stages. Drug-eluting balloons represent a relatively recent addition to the procedural approaches, which also include atherectomy, balloon angioplasty and stenting. In cases involving especially long lesions, bypass surgery can create a new route for blood flow around the diseased artery.

For more information: www.medtronic.com

Related Content

News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in
C.R. Bard, LEVANT 2 results, Lutonix 035 DCB, drug coated balloon, PTA
Feature | Drug-Eluting Balloons| July 08, 2015
C.R. Bard Inc. announced the publication of results from the LEVANT 2 study in the June 24, 2015, online issue of The...
Lutonix DCB, CMS, reimbursement, pass-through payment, outpatient use
News | Drug-Eluting Balloons| June 11, 2015
C.R. Bard Inc. announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has improved the pass-through...
IN.PACT Admiral, Global Study, DEB SFA-LONG, long peripheral lesions, EuroPCR
News | May 22, 2015
New clinical data from two different studies show the IN.PACT Admiral drug-coated balloon from Medtronic plc...
Stellarex, Spectranetics, investment, BTK, peripheral artery disease
News | May 06, 2015
The Spectranetics Corporation announced it is accelerating investments in the Stellarex drug-coated balloon angioplasty...
Videos | Drug-Eluting Balloons| April 02, 2015
The FDA recently approved the first two drug-coated balloons for the U.S.
Videos | Cath Lab| March 25, 2015
Hear the latest trends and news on interventional cardiology from the American College of Cardiology (ACC) 2015 meeti
Biotronik, Passeo-18 Lux, DCB, BIOLUX P-I, trial, drug eluting, balloon catheter
News | March 04, 2015
Biotronik announced that results of its BIOLUX P-I clinical study have been published in the Journal of Endovascular...
In.PACT Admiral, PAD, Medicare, pass-through payment, Medtronic, balloon cath
News | February 23, 2015
Medtronic announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-...
Bard, Lutonix, drug coated balloon, DCB, CMS, pass-through payment, outpatient
News | February 23, 2015
C. R. Bard Inc. announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a pass-through...
Overlay Init